Neo Ivy Capital Management Exelixis, Inc. Transaction History
Neo Ivy Capital Management
- $294 Million
- Q3 2024
A detailed history of Neo Ivy Capital Management transactions in Exelixis, Inc. stock. As of the latest transaction made, Neo Ivy Capital Management holds 10,210 shares of EXEL stock, worth $355,614. This represents 0.09% of its overall portfolio holdings.
Number of Shares
10,210Holding current value
$355,614% of portfolio
0.09%Shares
17 transactions
Others Institutions Holding EXEL
# of Institutions
501Shares Held
244MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.17 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$1.02 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$885 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$535 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$399 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.2B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...